Abstract
Background: Based on Chicago Classification version 3.0, the disorders of esophagogastric junction outflow obstruction (EGJOO) include achalasia (types I, II and III) and EGJOO. Although no curative treatments are currently available for the treatment of the disorders of EGJOO, medical treatments, endoscopic pneumatic dilation (PD), laparoscopic Heller myotomy (LHM), and per-oral endoscopic myotomy (POEM) are usually the sought-after modes of treatment. Since the etiology and pathogenesis might vary depending on the types of EGJOO disorders, treatment strategies should be considered based on those subtypes. Summary: Based on the accumulated evidences, the treatment strategies of our institution are as follows: effects of medical treatments on achalasia are limited. Either PD or LHM/POEM can be considered a first-line in achalasia type I, according to the patient's wish. PD and POEM can be considered first-line in achalasia types II and III, respectively. Conversely, In EGJOO, medical treatments including drugs like acotiamide and/or diltiazem can be tested as a first-line, and PD and POEM will be considered second and third-line treatments, respectively. Key Messages: The classification of subtypes based on high-resolution manometry will help us consider which treatment option can be selected as a first-line treatment depending upon the subtypes of disorders of EGJOO. Acotiamide has the potential to cure patients with EGJOO.
Journal Section:
Review
References
1.
Kahrilas PJ, Bredenoord AJ, Fox M, Gyawali CP, Roman S, Smout AJ, Pandolfino JE: The Chicago Classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil 2015;27:160-174.
[PubMed]
2.
Harnett KM, Cao W, Biancani P: Signal-transduction pathways that regulate smooth muscle function I. Signal transduction in phasic (esophageal) and tonic (gastroesophageal sphincter) smooth muscles. Am J Physiol Gastrointest Liver Physiol 2005;288:G407-G416.
[PubMed]
3.
Collman PI, Tremblay L, Diamant NE: The central vagal efferent supply to the esophagus and lower esophageal sphincter of the cat. Gastroenterology 1993;104:1430-1438.
[PubMed]
4.
Ghoshal UC, Daschakraborty SB, Singh R: Pathogenesis of achalasia cardia. World J Gastroenterol 2012;18:3050-3057.
[PubMed]
5.
Park W, Vaezi MF: Etiology and pathogenesis of achalasia: the current understanding. Am J Gastroenterol 2005;100:1404-1414.
[PubMed]
6.
Bardan E, Saeian K, Xie P, Ren J, Kern M, Dua K, Shaker R: Effect of pharyngeal stimulation on the motor function of the esophagus and its sphincters. Laryngoscope 1999;109:437-441.
[PubMed]
7.
Kahrilas PJ, Boeckxstaens G: The spectrum of achalasia: lessons from studies of pathophysiology and high-resolution manometry. Gastroenterology 2013;145:954-965.
[PubMed]
8.
Muta K, Ihara E, Fukaura K, Tsuchida O, Ochiai T, Nakamura K: Effects of acotiamide on the esophageal motility function in patients with esophageal motility disorders: a pilot study. Digestion 2016;94:9-16.
[PubMed]
9.
Lynch KL, Pandolfino JE, Howden CW, Kahrilas PJ: Major complications of pneumatic dilation and Heller myotomy for achalasia: single-center experience and systematic review of the literature. Am J Gastroenterol 2012;107:1817-1825.
[PubMed]
10.
Pandolfino JE, Gawron AJ: Achalasia: a systematic review. JAMA 2015;313:1841-1852.
[PubMed]
11.
Rohof WO, Salvador R, Annese V, Bruley des Varannes S, Chaussade S, Costantini M, Elizalde JI, Gaudric M, Smout AJ, Tack J, Busch OR, Zaninotto G, Boeckxstaens GE: Outcomes of treatment for achalasia depend on manometric subtype. Gastroenterology 2013;144:718-725; quiz e13-e14.
[PubMed]
12.
Inoue H, Sato H, Ikeda H, Onimaru M, Sato C, Minami H, Yokomichi H, Kobayashi Y, Grimes KL, Kudo SE: Per-oral endoscopic myotomy: a series of 500 patients. J Am Coll Surg 2015;221:256-264.
[PubMed]
13.
Bhayani NH, Kurian AA, Dunst CM, Sharata AM, Rieder E, Swanstrom LL: A comparative study on comprehensive, objective outcomes of laparoscopic Heller myotomy with per-oral endoscopic myotomy (POEM) for achalasia. Ann Surg 2014;259:1098-1103.
[PubMed]
14.
Bechara R, Ikeda H, Inoue H: Peroral endoscopic myotomy: an evolving treatment for achalasia. Nat Rev Gastroenterol Hepatol 2015;12:410-426.
[PubMed]
15.
Sharata AM, Dunst CM, Pescarus R, Shlomovitz E, Wille AJ, Reavis KM, Swanstrom LL: Peroral endoscopic myotomy (POEM) for esophageal primary motility disorders: analysis of 100 consecutive patients. J Gastrointest Surg 2015;19:161-170; discussion 170.
[PubMed]
16.
Bechara R, Ikeda H, Inoue H: Peroral endoscopic myotomy for jackhammer esophagus: to cut or not to cut the lower esophageal sphincter. Endosc Int Open 2016;4:E585-E588.
[PubMed]
17.
Perez-Fernandez MT, Santander C, Marinero A, Burgos-Santamaria D, Chavarria-Herbozo C: Characterization and follow-up of esophagogastric junction outflow obstruction detected by high resolution manometry. Neurogastroenterol Motil 2016;28:116-126.
[PubMed]
18.
van Hoeij FB, Smout AJ, Bredenoord AJ: Characterization of idiopathic esophagogastric junction outflow obstruction. Neurogastroenterol Motil 2015;27:1310-1316.
[PubMed]
19.
Kusunoki H, Haruma K, Manabe N, Imamura H, Kamada T, Shiotani A, Hata J, Sugioka H, Saito Y, Kato H, Tack J: Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography. Neurogastroenterol Motil 2012;24:540-545, e250-e251.
[PubMed]
20.
Kawachi M, Matsunaga Y, Tanaka T, Hori Y, Ito K, Nagahama K, Ozaki T, Inoue N, Toda R, Yoshii K, Hirayama M, Kawabata Y, Takei M: Acotiamide hydrochloride (Z-338) enhances gastric motility and emptying by inhibiting acetylcholinesterase activity in rats. Eur J Pharmacol 2011;666:218-225.
[PubMed]
© 2016 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2017
You do not currently have access to this content.
